XNAS · Healthcare · Biotechnology
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Q1 2026 | 0.89 | 0.76 | -14.61% | $766.2M | ❌ Miss | -1.06% | -5.19% | -1.44% |
| 2026-02-23 | Q4 2025 | 0.36 | 0.46 | +27.78% | $875.0M | ✅ Beat | -2.64% | -5.05% | -11.65% |
| 2025-10-27 |
| Q3 2025 |
| 0.51 |
| 0.12 |
| -76.47% |
| $776.1M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-04 | Q2 2025 | 0.93 | 1.44 | +54.84% | $825.4M | ✅ Beat | — | — | — |
| 2025-05-01 | Q1 2025 | 0.71 | 1.13 | +59.15% | $745.1M | ✅ Beat | — | — | — |
| 2025-02-19 | Q4 2024 | 0.74 | 0.92 | +24.32% | $747.0M | ✅ Beat | — | — | — |
| 2024-10-29 | Q3 2024 | 0.52 | 0.91 | +75.00% | $745.7M | ✅ Beat | — | — | — |
| 2024-08-05 | Q2 2024 | 0.35 | 0.96 | +174.29% | $712.0M | ✅ Beat | — | — | — |
Showing last 8 quarters.